Principal Investigator
Overview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT02039726
Status
Closed for Recruitment
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Jill Clark, Research Nurse
Phone
Email Address
Purpose of Study
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT02039726
Status
Closed for Recruitment
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Jill Clark, Research Nurse
Phone
Email Address
Purpose of Study
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
